Английская Википедия:GEMoaB Monoclonals
Шаблон:Use dmy dates Шаблон:Orphan
Шаблон:Infobox company GEMoaB is a biopharmaceutical company based in Dresden/Germany. The company has a broad pipeline of next generation immunotherapy product candidates for the treatment of advanced blood cancers and solid tumours in pre-clinical and clinical development. The company was founded in 2011 by the two university professors Gerhard Ehninger and Michael Bachmann.[1] [2] It was acquired by the new company AvenCell Therapeutics in 2021.[3][4]
Company background
Шаблон:See also To overcome the limitations of current cellular immunotherapies, GEMoaB has established two cellular immunotherapy platforms, which are called UniCAR & RevCAR. These genetically modified T-cells can be rapidly and repeatedly turned on and off via dosing of so-called Targeting Modules (TMs), which crosslink UniCAR/RevCAR T-effector cells with malignant target cells. Upon cross-linkage, UniCAR/RevCAR T-cells are activated and expanded and eliminate malignant target cells. They can be rapidly turned off after TM withdrawal, promising to avoid T-effector cell exhaustion and to reduce potential side effects typically associated with CAR-T therapies.[5]
Scientific and strategic board
The company's scientific and strategic board is composed of: Gerhard Ehninger (Chairman), Michael Bachmann (Germany), Katy Rezvani (U.S.A.), Bob Löwenberg (The Netherlands) as well as Thomas de Maizière, Member of Parliament (Germany).[6]
Co-operations
Gemoab co-operates with a range of partners: its sister company Cellex in Cologne, Germany, the Fraunhofer-Institut, the pharmaceutical company Bristol-Myers Squibb as well as the companies ABX, Bio Elpida and the federal Saxonian Ministry of Science and Research.[7]
Drugs currently under development
- GEM333: T-cell engaging bispecific antibody (TCE) against CD33 in AML[8][9]
- GEM3PSCA, TCE against PSCA in Prostate Cancer and other PSCA expressing solid tumours[10]
- UniCAR-T-CD 123 for the treatment of AML, ALL and certain lymphomas
- UniCAR-T-PSMA for the treatment of a number of PSMA expressing tumours
Literatur
- Nicola Mitwasi et al.: "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells In: Nature Scientific Reports, Band 10, 2020, S. 2141. Шаблон:Doi, Шаблон:PMID.
- Loff, S., Meyer, J.-E., Dietrich, J., Spehr, J., Julia, R., von Bonin, M., Gründer, C., Franke, K., Feldmann, A., Bachmann, M., Ehninger, G., Ehninger, A., Cartellieri, M.: Late-Stage Preclinical Characterization of Switchable CD123-Specific CAR-T for Treatment of Acute Leukemia In: Blood, 132, 2018, S. 964-964. Шаблон:Doi.
- Arndt, C., Feldmann, A., Koristka, S., Schafer, M., Bergmann, R., Mitwasi, N., Berndt, N., Bachmann, D., Kegler, A., Schmitz, M., Puentes-Cala, E., Soto, J.A., Ehninger, G., Pietzsch, J., Liolios, C., Wunderlich, G., Kotzerke, J., Kopka, K., Bachmann, M.: A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR In: Oncoimmunology, Band 8, 2019, Article: 1659095. Шаблон:Doi, Шаблон:PMID.
- C. Arndt, M. von Bonin et al.: Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. In: Leukemia, Band 27, Nummer 4, April 2013, S. 964–967, Шаблон:Doi, Шаблон:PMID.
See also
References
External links
- ↑ Get to know GEMoaB, Company Website, Retrieved: May 11, 2020
- ↑ Шаблон:Cite news
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ M. Cartellieri, A. Feldmann et al: Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. In: Blood Cancer Journal. Band 6, Nummer 8, 08 2016, S. e458, Шаблон:Doi, Шаблон:PMID, Шаблон:PMC.
- ↑ Scientific and Strategic Advisory Board, Company Website, Retrieved: May 11, 2020
- ↑ Our Partners, Company Website, Retrieved: May 11, 2020
- ↑ AML: GEM333-01, Nationales Centrum für Tumorerkrankungen Dresden, Retrieved: May 11, 2020
- ↑ Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia, clinicaltrials.gov, Retrieved: May 11, 2020
- ↑ Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker, clinicaltrials.gov, Retrieved: May 11, 2020
